Alexion Pharm Inc (ALXN) 135.61 $ALXN
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 246.13 (-4.33), BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), IBB: 267.60 (-5.98), REGN: 372.03 (-9.05)
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
BusinessWire - Fri Jun 10, 1:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).(1) In this study, once-monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase (LDH), a marker of hemolysis, in 100 percent of treated patients, which were observed through up to five once-monthly dosing intervals. Researchers also reported that, at this time, 80 percent of patients who required at least 1 blood transfusion in the 12 months prior to treatment with ALXN1210 did not require transfusions while on treatment.(2) These findings were presented in a late-breaking poster at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.
ALXN: 135.61 (-2.63)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 81.10 (-1.84), ALXN: 135.61 (-2.63), AEGR: 1.37 (-0.13), ACOR: 27.07 (-0.45)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), PXD: 159.55 (-4.65), ALXN: 135.61 (-2.63), HAL: 44.38 (-1.12), EOG: 81.56 (-3.02), AMGN: 154.78 (-2.00), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), COP: 44.51 (-2.06), JUNO: 42.98 (-2.55), CVX: 101.98 (-0.83), OXY: 75.45 (-0.15), REGN: 372.03 (-9.05)
Company News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Companies in the News are: HTZ,ALXN,VRX,UNFI
VRX: 24.14 (-1.34), UNFI: 42.35 (-1.45), HTZ: 10.68 (-0.50), ALXN: 135.61 (-2.63)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)
PR Newswire - Wed Jun 08, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. ("Alexion" or "the Company"
(NASDAQ: ALXN). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ALXN: 135.61 (-2.63)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Tue Jun 07, 5:20PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company" (Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
ALXN: 135.61 (-2.63)
Chevron and Zillow advance while Ralph Lauren skids
AP - Tue Jun 07, 4:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
VRX: 24.14 (-1.34), UNFI: 42.35 (-1.45), ALXN: 135.61 (-2.63), ZG: 32.46 (-0.22), CVX: 101.98 (-0.83), VZ: 52.67 (+0.72), RL: 95.80 (-0.38), VRX.TO: 30.80 (-1.39), Z: 32.22 (-0.06)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. -- ALXN
BusinessWire - Tue Jun 07, 12:04PM CDT
Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc. ("Alexion Pharmaceuticals" or the "Company" (NASDAQ:ALXN) concerning possible violations of federal securities laws.
ALXN: 135.61 (-2.63)
Look for Shares of Alexion Pharmaceuticals to Potentially Rebound after Yesterday's 10.88% Sell Off
Comtex SmarTrend(R) - Tue Jun 07, 11:50AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $136.14 to a high of $140.75. Yesterday, the shares fell 10.9%, which took the trading range below the 3-day low of $150.60 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 135.61 (-2.63)
Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN
PR Newswire - Tue Jun 07, 10:32AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Alexion Pharmaceuticals, Inc. ("Alexion" or the Company) (NASDAQ: ALXN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
ALXN: 135.61 (-2.63)
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris(R)) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
BusinessWire - Mon Jun 06, 3:01PM CDT
--- Detailed Results to be Presented at the 14th International Congress on Neuromuscular Diseases (ICNMD) July 7 in Toronto-
ALXN: 135.61 (-2.63)
Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 9:15AM CDT
Alexion Pharmaceuticals (ALXN) announced that ALXN1210 received orphan drug status in the EU for paroxysmal nocturnal hemoglobinuria.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)
European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
BusinessWire - Wed Jun 01, 3:05PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting C5 antibody being evaluated in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a debilitating, ultra-rare, life-threatening blood disorder in which uncontrolled activation of complement, a component of the immune system, results in hemolysis (destruction of a patient's red blood cells).
ALXN: 135.61 (-2.63)
Alexion Pharmaceuticals Rises 1.23% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 01, 1:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $149.89 to a high of $153.61. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $153.44 on volume of 496,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 135.61 (-2.63)
Alexion to Present at Upcoming Investor Conferences
BusinessWire - Tue May 31, 9:00AM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences:
ALXN: 135.61 (-2.63)
Look for Shares of Alexion Pharmaceuticals to Potentially Rebound after Yesterday's 2.42% Sell Off
Comtex SmarTrend(R) - Thu May 19, 2:58PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $138.63 to a high of $142.30. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $138.64 on volume of 525,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 135.61 (-2.63)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 246.13 (-4.33), BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), IBB: 267.60 (-5.98), REGN: 372.03 (-9.05)
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
BusinessWire - Fri Jun 10, 1:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).(1) In this study, once-monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase (LDH), a marker of hemolysis, in 100 percent of treated patients, which were observed through up to five once-monthly dosing intervals. Researchers also reported that, at this time, 80 percent of patients who required at least 1 blood transfusion in the 12 months prior to treatment with ALXN1210 did not require transfusions while on treatment.(2) These findings were presented in a late-breaking poster at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.
ALXN: 135.61 (-2.63)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 81.10 (-1.84), ALXN: 135.61 (-2.63), AEGR: 1.37 (-0.13), ACOR: 27.07 (-0.45)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), PXD: 159.55 (-4.65), ALXN: 135.61 (-2.63), HAL: 44.38 (-1.12), EOG: 81.56 (-3.02), AMGN: 154.78 (-2.00), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), COP: 44.51 (-2.06), JUNO: 42.98 (-2.55), CVX: 101.98 (-0.83), OXY: 75.45 (-0.15), REGN: 372.03 (-9.05)
Company News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Companies in the News are: HTZ,ALXN,VRX,UNFI
VRX: 24.14 (-1.34), UNFI: 42.35 (-1.45), HTZ: 10.68 (-0.50), ALXN: 135.61 (-2.63)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)
PR Newswire - Wed Jun 08, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. ("Alexion" or "the Company"
(NASDAQ: ALXN). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. ALXN: 135.61 (-2.63)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Tue Jun 07, 5:20PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company"
(Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. ALXN: 135.61 (-2.63)
Chevron and Zillow advance while Ralph Lauren skids
AP - Tue Jun 07, 4:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
VRX: 24.14 (-1.34), UNFI: 42.35 (-1.45), ALXN: 135.61 (-2.63), ZG: 32.46 (-0.22), CVX: 101.98 (-0.83), VZ: 52.67 (+0.72), RL: 95.80 (-0.38), VRX.TO: 30.80 (-1.39), Z: 32.22 (-0.06)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. -- ALXN
BusinessWire - Tue Jun 07, 12:04PM CDT
Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc. ("Alexion Pharmaceuticals" or the "Company"
(NASDAQ:ALXN) concerning possible violations of federal securities laws. ALXN: 135.61 (-2.63)
Look for Shares of Alexion Pharmaceuticals to Potentially Rebound after Yesterday's 10.88% Sell Off
Comtex SmarTrend(R) - Tue Jun 07, 11:50AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $136.14 to a high of $140.75. Yesterday, the shares fell 10.9%, which took the trading range below the 3-day low of $150.60 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 135.61 (-2.63)
Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN
PR Newswire - Tue Jun 07, 10:32AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Alexion Pharmaceuticals, Inc. ("Alexion" or the Company) (NASDAQ: ALXN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
ALXN: 135.61 (-2.63)
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris(R)) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
BusinessWire - Mon Jun 06, 3:01PM CDT
--- Detailed Results to be Presented at the 14th International Congress on Neuromuscular Diseases (ICNMD) July 7 in Toronto-
ALXN: 135.61 (-2.63)
Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 9:15AM CDT
Alexion Pharmaceuticals (ALXN) announced that ALXN1210 received orphan drug status in the EU for paroxysmal nocturnal hemoglobinuria.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), ALXN: 135.61 (-2.63), BMY: 72.65 (-0.08)
European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
BusinessWire - Wed Jun 01, 3:05PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting C5 antibody being evaluated in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a debilitating, ultra-rare, life-threatening blood disorder in which uncontrolled activation of complement, a component of the immune system, results in hemolysis (destruction of a patient's red blood cells).
ALXN: 135.61 (-2.63)
Alexion Pharmaceuticals Rises 1.23% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 01, 1:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $149.89 to a high of $153.61. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $153.44 on volume of 496,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 135.61 (-2.63)
Alexion to Present at Upcoming Investor Conferences
BusinessWire - Tue May 31, 9:00AM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences:
ALXN: 135.61 (-2.63)
Look for Shares of Alexion Pharmaceuticals to Potentially Rebound after Yesterday's 2.42% Sell Off
Comtex SmarTrend(R) - Thu May 19, 2:58PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $138.63 to a high of $142.30. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $138.64 on volume of 525,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 135.61 (-2.63)
